Trial Profile
A Phase I Study Investigating the Survival of HP802-247 Allogeneic Cells in Excisional Acute Cutaneous Wounds
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs HP 802247 (Primary)
- Indications Leg ulcer; Wounds
- Focus Pharmacodynamics
- Sponsors Smith & Nephew Biotherapeutics
- 30 Sep 2014 New trial record